3-amino-4-(2-chlorophenyl)-2-[(4-chlorophenyl)carbonyl]-6-methyl-N-phenyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-amino-4-(2-chlorophenyl)-2-[(4-chlorophenyl)carbonyl]-6-methyl-N-phenyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
• 英文别名: 3-amino-2-(4-chlorobenzoyl)-4-(2-chlorophenyl)-6-methyl-N-phenyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
• 化学式: C₂₈H₂₁Cl₂N₃O₂S
• 分子量: 534.5
• InChiKey: DXZOEINELIIZFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.5
• 重原子数：
  36
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• 4,7-DIHYDROTHIENO[2,3-B]PYRIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
  申请人：Gamber Gabriel G.

  公开号：US20090306373A1

  公开（公告）日：2009-12-10

  This invention relates generally to compounds and pharmaceutical compositions for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.

  本发明涉及一般用于治疗肌球蛋白重链（MyHC）介导的疾病，特别是心血管疾病的化合物和制药组合物。
• Methods For The Treatment Of Myosin Heavy Chain-Mediated Conditions Using 4,7-Dihydrothieno[2,3-B]Pyridine Compounds
  申请人：Gamber Gabriel G.

  公开号：US20110105496A1

  公开（公告）日：2011-05-05

  This invention relates generally to methods for the treatment of myosin heavy chain (MyHC)-mediated conditions, and in particular, cardiovascular conditions.

  本发明涉及治疗肌球蛋白重链（MyHC）介导的疾病的方法，特别是心血管疾病的方法。
• Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases
  申请人：Ansorge Siegfried

  公开号：US20070037785A1

  公开（公告）日：2007-02-15

  The present invention relates to substances capable of specifically inhibiting Gly-Pro-p-nitroanilide cleaving peptidases, for a use in the medical field. Furthermore, the invention relates to the use of at least one of such substances or of at least one pharmaceutical or cosmetic composition containing at least one such substance for a prophylaxis or a therapy of diseases, particularly for a prophylaxis and a therapy of diseases accompanied by an excessive immune response (autoimmune diseases, allergies, transplant rejections), of other chronic-inflammatory diseases, of neuronal diseases and cerebral damage, of skin diseases (inter alia acne, psoriasis), of tumor diseases and of specific virus infections (inter alia SARS).